IRE1α modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancer

Abstract

Aim: Muscle-invasive bladder cancer (MIBC) remains lethal despite promising oncolytic virotherapy, hindered by tumor-intrinsic resistance. This study aimed to elucidate the molecular basis underlying differential sensitivity to the oncolytic M1 virus in bladder cancer.

Methods: Bladder cancer cell lines with varying sensitivity to M1 were analyzed for endoplasmic reticulum (ER) stress responses and unfolded protein response (UPR) pathway activation. IRE1α expression was modulated using small interfering RNA and a selective inhibitor. Viral cytotoxicity, replication, and apoptosis were assessed using viability assays, immunofluorescence, electron microscopy, and immunoblotting. In vivo antitumor efficacy was assessed using xenografted mice. Clinical relevance was examined using patient-derived cells and survival data from The Cancer Genome Atlas.

Results: M1 virus induced ER stress and apoptosis in sensitive cells (e.g., T24, UM-UC-3) supporting viral protein expression, whereas low-sensitivity cells like EJ showed minimal response due to limited viral replication. In moderately sensitive cells, M1 replication led to viral protein accumulation, triggering IRE1α upregulation, which in turn limited further protein buildup and apoptosis. IRE1α inhibition enhanced M1-induced ER stress, apoptotic signaling, and oncolysis without affecting viral replication capacity. In vivo, M1 plus STF083010 achieved greater tumor suppression than monotherapy without added toxicity. Analysis of patient-derived cells and TCGA data further revealed downregulation of IRE1α in primary tumors and its potential association with worse prognosis.

Conclusion: IRE1α modulates M1-induced viral protein accumulation and cell death. Inhibiting IRE1α enhances ER stress and potentiates the oncolytic effect of M1 virus. Targeting IRE1α may improve M1-based virotherapy outcomes in accessible tumors.

Keywords

Oncolytic M1 virus / IRE1α / ER stress / UPR / bladder cancer

References

[1] Zhang Y,Li M,Pan H.The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040.J Glob Health2023;13:04109 PMCID:PMC10502766

[2] Wéber A,Shah R.Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates.World J Urol2024;42:237 PMCID:PMC11021283

[3] Leslie SW,Aeddula NR. Bladder cancer. StatPearls. Treasure Island (FL); 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536923/. [Last accessed on 12 Aug 2025]

[4] Grabe-Heyne K,Mariappan P,Pöhlmann J.Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.Front Oncol2023;13:1170124 PMCID:PMC10272547

[5] Yang Y,Li Z,Li Y.Precise diagnosis and treatment of non-muscle invasive bladder cancer - a clinical perspective.Front Oncol2023;13:1042552 PMCID:PMC9927396

[6] Kodera A,Lim P,Elhadi M.The management of Bacillus Calmette-Guérin (BCG) failure in high-risk non-muscle invasive bladder cancer: a review article.Cureus2023;15:e40962 PMCID:PMC10369196

[7] Ferro M,Lucarelli G.Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study.Minerva Urol Nephrol2021;73:796-802

[8] Germuth FG Jr,Taylor JJ.Antibasement membrane disease. I. The glomerular lesions of Goodpasture’s disease and experimental disease in sheep.Johns Hopkins Med J1972;131:367-84

[9] Zhang H,Wang W,Li C.Efficacy and safety of radical cystectomy with ileal conduit for muscle-invasive bladder cancer in the elderly: a multicenter retrospective study.Front Oncol2024;14:1402360 PMCID:PMC11300965

[10] Teply BA.Systemic therapy for bladder cancer - a medical oncologist’s perspective.J Solid Tumors2014;4:25-35 PMCID:PMC4232954

[11] Hensley PJ,Campbell MT.Progression of disease after Bacillus Calmette-Guérin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy.J Urol2021;206:1258-67 PMCID:PMC11902300

[12] Hu X,Wu S.Advances in diagnosis and therapy for bladder cancer.Cancers2022;14:3181 PMCID:PMC9265007

[13] Wilson F,Choudhury A.Biomarkers in muscle invasive bladder cancer.Adv Clin Chem2022;107:265-97

[14] Rahman MM.Oncolytic viruses: newest frontier for cancer immunotherapy.Cancers2021;13:5452 PMCID:PMC8582515

[15] Ma R,Chiocca EA,Yu J.The emerging field of oncolytic virus-based cancer immunotherapy.Trends Cancer2023;9:122-39 PMCID:PMC9877109

[16] Kaufman HL,Zloza A.Oncolytic viruses: a new class of immunotherapy drugs.Nat Rev Drug Discov2015;14:642-62 PMCID:PMC7097180

[17] Xue C,Yang B.Gene therapy in polycystic kidney disease: a promising future.J Transl Int Med2024;12:543-52 PMCID:PMC11720931

[18] Hu H,Hu J.Oncolytic viruses for the treatment of bladder cancer: advances, challenges, and prospects.J Clin Med2022;11:6997 PMCID:PMC9738443

[19] Filon M.New treatment options for non-muscle-invasive bladder cancer.Am Soc Clin Oncol Educ Book2025;45:e471942

[20] Liu X,Feng K.Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: a meta-analysis.Front Pharmacol2022;13:1023533 PMCID:PMC9702820

[21] Liu C,Lin B.Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy.Adv Sci2024;11:e2401061 PMCID:PMC11186051

[22] Yuan S,Jiang S,Peng J.Endoplasmic reticulum stress and therapeutic strategies in metabolic, neurodegenerative diseases and cancer.Mol Med2024;30:40 PMCID:PMC10956371

[23] Cao T,Zhou X.Integrated signaling system under endoplasmic reticulum stress in eukaryotic microorganisms.Appl Microbiol Biotechnol2021;105:4805-18

[24] Zheng Q,He JC.Progress in therapeutic targets on podocyte for Alport syndrome.J Transl Int Med2024;12:129-33 PMCID:PMC11135632

[25] Kim P.Understanding the unfolded protein response (UPR) pathway: insights into neuropsychiatric disorders and therapeutic potentials.Biomol Ther2024;32:183-91 PMCID:PMC10902702

[26] Panayi GS.Immunoglobulin heavy-chain-binding protein (BiP): a stress protein that has the potential to be a novel therapy for rheumatoid arthritis.Biochem Soc Trans2014;42:1752-5

[27] Haeri M.Endoplasmic reticulum stress and unfolded protein response pathways: potential for treating age-related retinal degeneration.J Ophthalmic Vis Res2012;7:45-59 PMCID:PMC3381108

[28] Lebeaupin C,Kaufman RJ.The impact of the ER unfolded protein response on cancer initiation and progression: therapeutic implications. In: Mendillo ML, Pincus D, Scherz-Shouval R, editors. HSF1 and molecular chaperones in biology and cancer. Cham: Springer International Publishing; 2020. pp. 113-31. PMCID:PMC7243802

[29] da Fonseca FG, Serufo ÂV, Leão TL, Lourenço KL. Viral infections and their ability to modulate endoplasmic reticulum stress response pathways.Viruses2024;16:1555 PMCID:PMC11512299

[30] Cai J,Zhang H.Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.Proc Natl Acad Sci U S A2017;114:6812-7 PMCID:PMC5495246

[31] Chen XY,Zhu WB.Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer.iScience2024;27:111148 PMCID:PMC11565026

[32] Lin Y,Liang J.Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers.Proc Natl Acad Sci U S A2014;111:E4504-12 PMCID:PMC4210284

[33] Hu C,Lin Y.Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer.Cell Death Dis2018;9:274 PMCID:PMC5833719

[34] Wang L,Cheng Z.Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.J Immunother Cancer2022;10:e004167 PMCID:PMC9157365

[35] Qiu L,Jaishankar D.Beyond UPR: cell-specific roles of ER stress sensor IRE1α in kidney ischemic injury and transplant rejection.Kidney Int2023;104:463-9 PMCID:PMC10519186

[36] Zhang K,Malhotra J.The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis.EMBO J2011;30:1357-75 PMCID:PMC3094110

[37] Fu F.IRE1/XBP1 and endoplasmic reticulum signaling - from basic to translational research for cardiovascular disease.Curr Opin Physiol2022;28:100552 PMCID:PMC10195104

[38] Shao R,Xue R.Tumor-derived exosomal ENO2 modulates polarization of tumor-associated macrophages through reprogramming glycolysis to promote progression of diffuse large B-cell lymphoma.Int J Biol Sci2024;20:848-63 PMCID:PMC10797692

[39] Liu Y,Hu C.ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC.Cancer Drug Resist2025;8:25 PMCID:PMC12159605

[40] Zhang YZ,Ma E.Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma.Cancer Drug Resist2025;8:10 PMCID:PMC11883234

[41] Kmiec D,Ficarelli M,Neil SJD.S-farnesylation is essential for antiviral activity of the long ZAP isoform against RNA viruses with diverse replication strategies.PLoS Pathog2021;17:e1009726 PMCID:PMC8568172

[42] Zimmer MM,Rand U.The short isoform of the host antiviral protein ZAP acts as an inhibitor of SARS-CoV-2 programmed ribosomal frameshifting.Nat Commun2021;12:7193 PMCID:PMC8664833